Drug shortage
Remifentanil Hydrochloride Injection · Hikma Pharmaceuticals USA, Inc.
FDA drug shortage · Current · updated Apr 17, 2025
Key facts
| Generic name | Remifentanil Hydrochloride Injection |
|---|---|
| Proprietary name | Remifentanil Hydrochloride |
| Company | Hikma Pharmaceuticals USA, Inc. |
| Presentation | Remifentanil Hydrochloride, Injection, 5 mg per vial (NDC 0143-9393-10) |
| Dosage form | Injection |
| Strength | 5 mg per vial |
| Status | Current |
| Reason for shortage | Demand increase for the drug |
| Therapeutic category | Analgesia/Addiction |
| Package NDCs | 0143-9393-10 |
| First posted | Jun 28, 2022 |
| Last updated | Apr 17, 2025 |
At a glance
- 1–9 Package NDCs affected
- 10–99 FDA shortage records for this drug
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA drug shortages
The FDA Drug Shortages Database lists current and resolved shortages of drugs, with presentations, affected NDCs and reasons reported by manufacturers.
Source: U.S. Food and Drug Administration (FDA), Drug Shortages Database · Source date: